Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Primary Lymphoid Organs01:16

Primary Lymphoid Organs

1.5K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
1.5K
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

982
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
982
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

1.7K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

No association of prior administration of selected vaccines with lymphoma prognosis.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same author

A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma.

Blood cancer discovery·2026
Same author

Outcomes From the Multicenter ACCRU-LY-1804/CARiBOU TRIAL (Cytarabine, Acalabrutinib and Rituximab Integrated With Bortezomib-Based Outpatient Therapy) in 1st Line Mantle Cell Lymphoma.

American journal of hematology·2026
Same author

Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab.

Blood advances·2026
Same author

Development and Validation of a Novel Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma.

American journal of hematology·2026
Same author

Health Equity for Oncology Patients in Rural America: Insurmountable Challenges or Opportunity to Make a Real Difference.

JCO oncology practice·2026
Same journal

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

Blood advances·2026
Same journal

Spatial transcriptomics identifies a suppressive, T-cell excluded tumor microenvironment in extramedullary myeloma.

Blood advances·2026
Same journal

Venous Thromboembolism in Women on Estrogen Therapy: Presentation, Management, and Outcomes in the RIETE registry.

Blood advances·2026
Same journal

Diagnosis of NK-Large Granular Lymphocytic Leukemia.

Blood advances·2026
Same journal

A Phase Ib/II study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML.

Blood advances·2026
Same journal

Selective degradation of platelet BTK by PROTAC NX-5948 provides antithrombotic benefits without affecting haemostasis.

Blood advances·2026
See all related articles

Related Experiment Video

Updated: Jun 27, 2025

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

21.1K

Defining primary refractory large B-cell lymphoma.

Allison M Bock1,2, Raphael Mwangi3, Yucai Wang1

  • 1Division of Hematology, Mayo Clinic, Rochester, MN.

Blood Advances
|April 26, 2024
PubMed
Summary
This summary is machine-generated.

Defining primary refractory large B-cell lymphoma (LBCL) is crucial. Patients with progressive disease (PD) during frontline treatment have significantly worse survival, suggesting a refined definition for primary refractory LBCL.

More Related Videos

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking
11:39

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking

Published on: October 23, 2019

11.4K
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.1K

Related Experiment Videos

Last Updated: Jun 27, 2025

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

21.1K
Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking
11:39

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking

Published on: October 23, 2019

11.4K
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.1K

Area of Science:

  • Hematology
  • Oncology
  • Epidemiology

Background:

  • Large B-cell lymphoma (LBCL) patients not achieving complete response or relapsing early after immunochemotherapy (IC) have poor prognoses.
  • Current definitions of primary refractory disease vary, impacting clinical practice and research.

Purpose of the Study:

  • To examine variations in defining refractory status based on time to relapse.
  • To assess the association between different definitions of primary refractory LBCL and survival outcomes.

Main Methods:

  • Analysis of two independent cohorts: Molecular Epidemiological Resource (MER; N=949) and Lymphoma Epidemiology of Outcomes (LEO; N=2755).
  • LBCL patients diagnosed with newly diagnosed LBCL enrolled from September 2002 to May 2021.
  • Primary refractory LBCL defined by primary progressive disease (PPD), partial response (PR), or early relapse (3-12 months post-CR).

Main Results:

  • Patients with primary progressive disease (PPD) exhibited significantly inferior overall survival (OS) compared to those with partial response or early relapse.
  • In the MER cohort, 2-year OS rates were 15% for PPD versus 38% for PR and 44% for early relapse.
  • In the LEO cohort, 2-year OS rates were 31% for PPD versus 50% for PR and 58% for early relapse.

Conclusions:

  • Patients experiencing stable disease (SD) or progressive disease (PD) during frontline IC represent a distinct subgroup with poor outcomes.
  • A refined definition of primary refractory LBCL as SD or PD during or by the end of frontline treatment is proposed.